- Home
- FT vs SCPH Comparison
FT vs SCPH Comparison
Compare FT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- SCPH
- Stock Information
- Founded
- FT 1988
- SCPH 2013
- Country
- FT United States
- SCPH United States
- Employees
- FT N/A
- SCPH N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- SCPH Health Care
- Exchange
- FT Nasdaq
- SCPH Nasdaq
- Market Cap
- FT 192.5M
- SCPH 299.0M
- IPO Year
- FT N/A
- SCPH 2017
- Fundamental
- Price
- FT $7.95
- SCPH $5.63
- Analyst Decision
- FT
- SCPH Buy
- Analyst Count
- FT 0
- SCPH 3
- Target Price
- FT N/A
- SCPH $12.00
- AVG Volume (30 Days)
- FT 63.0K
- SCPH 2.3M
- Earning Date
- FT 01-01-0001
- SCPH 11-12-2025
- Dividend Yield
- FT 7.85%
- SCPH N/A
- EPS Growth
- FT N/A
- SCPH N/A
- EPS
- FT N/A
- SCPH N/A
- Revenue
- FT N/A
- SCPH $49,969,000.00
- Revenue This Year
- FT N/A
- SCPH $108.95
- Revenue Next Year
- FT N/A
- SCPH $78.30
- P/E Ratio
- FT N/A
- SCPH N/A
- Revenue Growth
- FT N/A
- SCPH 107.79
- 52 Week Low
- FT $5.97
- SCPH $1.94
- 52 Week High
- FT $7.23
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- FT 56.04
- SCPH 64.10
- Support Level
- FT $7.86
- SCPH $4.33
- Resistance Level
- FT $7.99
- SCPH $5.62
- Average True Range (ATR)
- FT 0.07
- SCPH 0.04
- MACD
- FT -0.00
- SCPH 0.01
- Stochastic Oscillator
- FT 71.87
- SCPH 89.29
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.